QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.106.109702v1 320/1/458    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stevens, M. J. Articles by Obrosova, I. G. Search for Related Content PubMed PubMed Citation Articles by Stevens, M. J. Articles by Obrosova, I. G.

ENDOCRINE AND DIABETES

Nicotinamide Reverses Neurological and Neurovascular Deficits in Streptozotocin Diabetic Rats

Division of Medical Sciences, The Medical School, University of Birmingham, Edgbaston, Birmingham, United Kingdom (M.J.S.); Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan (M.J.S., F.L., O.I.A., H.K., D.B., D.L.); and Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana (I.G.O., V.R.D.)

In diabetes, activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) is an important effector of oxidative-nitrosative injury, which contributes to the development of experimental diabetic peripheral neuropathy (DPN). However, the potential toxicity of complete PARP inhibition necessitates the utilization of weaker PARP inhibitors with additional therapeutic properties. Nicotinamide (vitamin B₃) is a weak PARP inhibitor, antioxidant, and calcium modulator and can improve energy status and inhibit cell death in ischemic tissues. We report the dose-dependent effects of nicotinamide in an established model of early DPN. Control and streptozotocin-diabetic rats were treated with 200 to 400 mg/kg/day nicotinamide (i.p.) for 2 weeks after 2 weeks of untreated diabetes. Sciatic endoneurial nutritive blood flow was measured by microelectrode polarography and hydrogen clearance, and sciatic motor and hind-limb digital sensory nerve conduction velocities and thermal and mechanical algesia were measured by standard electrophysiological and behavioral tests. Malondialdehyde plus 4-hydroxyalkenal concentration in the sciatic nerve and amino acid-(4)-hydroxynonenal adduct and poly(ADP-ribosyl)ated protein expression in human Schwann cells were assessed by a colorimetric method with N-methyl-2-phenyl indole and Western blot analysis, respectively. Nicotinamide corrected increased sciatic nerve lipid peroxidation in concert with nerve perfusion deficits and dose-dependently attenuated nerve conduction slowing, as well as mechanical and thermal hyperalgesia. Nicotinamide (25 mM) prevented high (30 mM) glucose-induced overexpression of amino acid-(4)-hydroxynonenal adducts and poly(ADP-ribosyl)ated proteins in human Schwann cells. In conclusion, nicotinamide deserves consideration as an attractive, nontoxic therapy for the treatment of DPN.

Address correspondence to: Dr. Martin John Stevens, Division of Medical Sciences, The Medical School, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK. E-mail: m.j.stevens{at}bham.ac.uk

This article has been cited by other articles:

				I. G. Obrosova, V. R. Drel, C. L. Oltman, N. Mashtalir, J. Tibrewala, J. T. Groves, and M. A. Yorek Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1645 - E1655. [Abstract] [Full Text] [PDF]